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ABSTRACT: We report the synthesis, characterization and antiproliferative activity of organo-osmium(II) and organo-
ruthenium(II) half-sandwich complexes [(η6-p-cym)Os(L)Cl]Cl (1 and 2) and [(η6-p-cym)Ru(L)Cl]Cl (3 and 4), where L = 
N-(2-hydroxy)-3-metoxybenzylidenethiosemicarbazide (L1) or N-(2,3-dihydroxybenzylidene)-3-phenylthiosemicarbazide 
(L2), respectively. X-ray crystallography showed that all four complexes possess half-sandwich pseudo-octahedral “three-
leg piano-stool” structures, with a neutral N,S-chelating thiosemicarbazone ligand and a terminal chloride occupying 
three coordinative positions. In methanol, E/Z isomerization of the coordinated thiosemicarbazone ligand was observed, 
while in an aprotic solvent like acetone, partial dissociation of the ligand occurs, reaching complete displacement in a 
more coordinating solvent like DMSO. In general, the complexes exhibited good activity towards A2780 ovarian, 
A2780Cis cisplatin-resistant ovarian, A549 lung, HCT116 colon, and PC3 prostate cancer cells. In particular ruthenium 
complex 3 does not present cross-resistance with the clinical drug cisplatin in the A2780 human ovarian cancer cell line. 
The complexes were more active than the free thiosemicarbazone ligands, especially in A549 and HCT116 cells with po-
tency improvements of up to 20-fold between the organic ligand L1 and the ruthenium complex 1. 
INTRODUCTION  
The discovery of highly efficient anticancer drugs with 
increased selectivity and less toxic side effects is an area 
of intense research in bioinorganic chemistry.1 Thiosemi-
carbazones (TSCs) and their metal complexes display a 
wide spectrum of biological activities,2,3,4,5 in particular 
they possess anticancer, antibacterial and antiviral prop-
erties.6,7,8 A variety of cellular mechanisms of action ap-
pears to be involved in the activity of this class of ligands,9 
including the inhibition of cellular iron uptake by trans-
ferrin,10,11,12 the mobilization of iron from cells,6,7,8 the in-
hibition of ribonucleotide reductase activity,13,14,15 the up-
regulation of the metastasis suppressor protein, N-myc 
downstream regulated gene I,16,17 and the formation of re-
dox active metal complexes that produce reactive oxygen 
species.11,18,19,20 Moreover, various studies21 have demon-
strated that the biological properties of TSC ligands can 
be modified and improved upon binding to transition 
metal ions.6,22  Metal coordination presents an opportuni-
ty to improve synergistically the efficacy of a biologically 
active organic scaffold23 such as lipophilicity, which influ-
ences cell permeability.24 Diversity arises from not only 
the choice of the metal itself and its oxidation state, but 
also from the type and number of coordinated ligands, as 
well as the coordination geometry of the complex.23  
Metal complexes of TSCs are playing a promising role in 
anticancer research, as is evident form the number of re-
cent publications.8,25 ,26 ,27  Platinum drugs are still widely 
used to treat cancer,5,28 but their therapeutic use can be 
limited by intrinsic or acquired resistance and by the oc-
currence of numerous deleterious side effects.29,30 It is im-
perative therefore, to develop new and more effective 
drugs. Ruthenium, a second row transition metal, contin-
ues to attract much attention,31,32 as its complexes have 
long been known to be well suited for biological applica-
tions.33,34 Organometallic Ru(II) complexes with half-
sandwich structure have demonstrated anti-proliferative 
potential,35 and there are numerous possibilities to modu-
late their biological and pharmacological properties by 
the appropriate choice of the ligands.11,36 In particular, the 
presence of a chelating ligand offers structural stability 
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and the opportunity to tune the electronic and steric fea-
tures of the complex.37 Additional features to be consid-
ered include water solubility and air stability.37,38 The bio-
logical activity of osmium compounds has been much less 
explored, perhaps because of the reputation of osmium 
(as osmium tetroxide) as being highly toxic.39 Neverthe-
less, several half sandwich piano-stool osmium(II) com-
plexes have exhibited promising in vitro activity and no 
cisplatin cross-resistance.40,41,42  Investigations of osmium 
complexes as alternatives to ruthenium-based anticancer 
agents have resulted in structurally diverse libraries of 
osmium complexes with different oxidation states and 
nuclearity.4 3 ,4 4 ,4 5 ,4 6  
Organometallic chemistry offers a potentially rich field 
for biological and medicinal application;47 however, lack 
of understanding of the aqueous chemistry of the organ-
ometallic complexes has emerged as a major obstacle for 
further developments. This is particularly true for osmi-
um(II) arene complexes.48 Third row transition metals are 
more inert than those of the first and second row. For ex-
ample, aquation of Pt(II) chlorido complexes often occurs 
up to 104 times more slowly compared to the lighter con-
gener Pd(II), and similarly organo-Os(II) complexes react 
typically 100 times more slowly than Ru(II).49,50,51 Howev-
er, reports on ruthenium arene complexes have shown 
that their aqueous reactivity is highly dependent on the 
nature of the coordinated ligands, as well as the arene, 
rather than on the metal and its oxidation state alone.52,53 
The aim of the present study is to investigate the reactivi-
ty in solution and the antiproliferative activity toward 
cancer cells of two Os(II) complexes [(η6-p-
cym)Os(L)Cl]Cl (1 and 2) and two analogous Ru(II) com-
plexes [(η6-p-cym)Ru(L)Cl]Cl (3 and 4), where L = N-(2-
hydroxy)-3-metoxybenzylidenethiosemicarbazide (L1) or 
N-(2,3-dihydroxybenzylidene)-3-phenylthiosemicarbazide 
(L2), respectively (Figure 1). This type of ligands, which 
could in principle be tridentate, can confer solution sta-
bility on their metal complexes; moreover they have 
shown interesting cytotoxic properties54 and could offer 
synergic antitumor activity. Different substituents were 
considered for ligands L1 and L2 on both the phenyl ring 
and at the N(3) nitrogen, since this can modulate lipo-
philicity and/or complex-substrate interactions. The solu-
tion behaviour of complexes 1-4 was studied both in a 
protic solvents such as methanol or water/DMSO mixture 
and in coordinating aprotic solvents like acetone, DMSO 
and DMF. The antiproliferative activity of 1-4 was evalu-
ated for A2780 human ovarian carcinoma and its cisplatin 
resistant variant A2780Cis, A549 lung, HCT116 colon and 
PC3 prostate tumor cell lines. 
RESULTS AND DISCUSSION  
Synthesis and characterization of the complexes. The 
ligands N-(2-hydroxy)-3-
metoxybenzylidenethiosemicarbazide (L1) and N-(2,3-
dihydroxybenzylidene)-3-phenylthiosemicarbazide (L2) 
were synthesized according to previously reported proce-
dures.54,55  
The reactions between [(η6-p-cym)MCl2]2 (M= Os, Ru) 
and the corresponding thiosemicarbazone ligands were 
carried out in a mixture of dry CH3OH and CH2Cl2 at
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ambient temperature and led to the isolation of pseudo 
octahedral complexes 1-4 of general formula [(η6-p-
cym)M(L)Cl]Cl in good yields. The identity of the com-
plexes was verified by 1H-NMR spectroscopy, and ESI-MS 
spectrometry, and their structures were confirmed by sin-
gle crystal X-ray crystallography. In all cases, the metal 
coordinates to a chloride ion, a η6-p-cymene ring and a 
NS-bidentate thiosemicarbazone chelating ligand. One 
chloride is present as the counterion (Figure 1). 
X-ray crystallographic studies. Crystals suitable for X-
ray diffraction analysis were obtained by slow evaporation 
of saturated solutions in methanol for compounds 1 and 3 
and in acetone for compounds 2 and 4. The crystal struc-
tures and atomic numbering schemes for [(η6-p-
cym)Os(L1)Cl]Cl (1), [(η6-p-cym)Os(L2)Cl]Cl∙(CH3)2CO 
(2∙(CH3)2CO), [(η6-p-cym)Ru(L1)Cl]Cl (3) and [(η6-p-
cym)Ru(L2)Cl]Cl∙(CH3)2CO (4∙(CH3)2CO) are shown in 
Figure 2. Selected bond lengths and angles are listed in 
Table 1, other crystallographic data are reported in Table 
S1. Complexes 1 and 3 crystallize in the orthorhombic sys-
tem with the chiral space group P212121, while complexes 2 
and 4 crystallize in triclinic system with centrosymmetric 
space group P-1. Both 2 and 4 crystallize with an acetone 
solvent molecule. The complexes adopt the expected half-
sandwich pseudo-octahedral “three leg piano-stool” ge-
ometry with η6-p-cymene as the seat and the neutral N,S-
chelating TSC ligand and a terminal chloride as the three 
legs. The positive charge of the complex is balanced by a 
chloride counterion. It is notable that in all the complex-
es, the ligand is present as the E isomer. 
In 1 and 3, the uncoordinated chloride anion forms a 
NH···Cl hydrogen bond respectively of 3.034(4) Å and 
175.1° for 1 and 3.031(3) and 176.7° for 3. In 2 and 4 a similar 
H-bond occurs between the uncoordinated chloride and 
the 3-OH group of the aromatic ring with a bond distance 
OH···Cl of 3.0651(16) and 169.0° for 2 and 3.0605(9) and 
168.7° for 4. The thiosemicarbazone ligands bind to the 
metal center through the imine nitrogen and the thione 
sulfur forming a five member chelate ring with an angle of 
82° for N-Ru-S, indicating a distortion from a regular  
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Figure 2. X-Ray crystal structures of complexes 1-4 with thermal ellipsoids drawn at 50% probability. Hydrogens are drawn as 
fixed-size spheres of 0.11 Å of radius and solvent molecules have been omitted for clarity. The edge-to-face stacking between one 
of the hydrogens of the p-cymene ring and an aromatic ring of the thiosemicarbazone ligands is indicated. 
 
Table 1. Selected bond lengths (Å) and angles (°) for complexes 1-4.  
  Bond distance (Å)  Bond angle (°) 
1     
 Os1-Cl1 2.4113(12) S1-Os1-Cl1 86.52(4) 
 Os1-S1 2.3551(13) N4-Os1-Cl1 81.63(10) 
 Os1-N4 2.118(4) N4-Os1-S1 81.63(11) 
 S1-C2 1.695(5)   
 H14-CE1 2.563   
2∙(CH3)2CO     
 Os1-Cl1 2.4030(5) S8-Os1-Cl1 87.81(2) 
 Os1-S8 2.3527(5) N4-Os1-Cl1 83.44(5) 
 Os1-N10 2.1227(17) N10-Os1-S8 81.79(5) 
 S8-C8 1.693(2)   
 H21-CE1 2.500   
3     
 Ru1-Cl1 2.4046(11) S1-Ru1-Cl1 86.90(4) 
 Ru1-S1 2.3501(10) N4-Ru1-Cl1 83.06(9) 
 Ru1-N4 2.125(3) N4-Ru1-S1 81.95(10) 
 S1-C2 1.695(4)   
 H14-CE1 2.548   
4∙(CH3)2CO     
 Ru1-Cl1 2.3993(3) S8- Ru1-Cl1 88.338(11) 
 Ru1-S8 2.3508(3) N10- Ru1-Cl1 84.77(3) 
 Ru1-N10 2.1256(9) N10- Ru1-S8 81.94(3) 
 S8-C8 1.6923(12)   
 H21-CE1 2.486   
 
octahedron, in analogy with similar Ru-arene thiosemi-
carbazone complexes.56 The length of the S-C bond (~1.69 
Å) is in accord with a double bond nature; in the free lig-
ands it is ~1.69-1.70 Å.57,58,59  
It is worth noting that in some osmium(II) and rutheni-
um(II) arene complexes, the potentially NNO tridentate 
hydrazone ligands behave as NN bidentate ligands. It has 
been  highlighted that the ligands are not flexible enough 
to occupy a facial arrangement in the complex and are 
therefore bidentate.6 0  An analogous situation could occur 
with L1 and L2, that can span the three facial coordina-
tion sites of the metal only with difficulty. Interestingly, 
these hydrazone ligands were found in both E and Z con-
figuration upon complexation with Ru(II) and Os(II). The 
dihedral angles between the aromatic ring plane and the 
thiosemicarbazones are 
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Figure 3. Aromatic region of the time-dependent 1H-NMR 
spectrum of 1 in MeOD-d4 at T = 298 K followed over 30 days. 
E and Z isomers are labelled as a and b set, respectively. The 
percentage of the Z isomer (b set) increases with time. 
 
around 70° in complexes 1 and 3 and about 78° in 2 and 4. 
Usually, this type of ligand adopts a flat confor-
mation:58,59,61 in our structures the lack of coplanarity is 
related to metal coordination. In the crystal structures of 
1-4, the same T-shaped edge-to-face stacking π interac-
tions, between one of the hydrogens of the p-cymene ring 
and the π electron density of the aromatic ring of the thi-
osemicarbazone ligands, are observed (distances from 
2.50 to 2.86 Å, Figure 2). 
Solution studies. 1H-NMR studies were used to investi-
gate the stability of the four complexes in various sol-
vents. 1H NMR spectra of 1-4 were firstly recorded in 
MeOD-d4, due to their low solubility in chlorinated sol-
vents such as chloroform or dichloromethane. For all the 
metal complexes, the spectra displayed just one set of sig-
nals, corresponding to the E isomer of the bidentate lig-
and coordinated to the metal center, the isomer in the 
crystallized complexes. The aromatic protons of the thio-
semicarbazone ligands displayed peaks between 6.5 and 
8.2 ppm and the iminic protons between 8.7 and 8.9 ppm, 
as expected for the ligand in the E form.55,62 The complex-
es contain chiral metal centers and in the 1H-NMR spectra 
recorded at 298 K a doublet is present for each p-cymene 
proton in the range 4.90-5.90 ppm; the isopropyl methyl 
groups appear as two doublets at 1.1 and 1.2 ppm. The res-
onance of one proton of the p-cymene ring displays a 
marked high-field shift in comparison with the other p-
cymene protons, in particular up to 4.90 ppm for osmium 
compounds 1 and 2 and 4.87 for ruthenium 3 and 4 (Fig-
ure 3). This is likely due to edge-to face -interaction be-
tween the C-H hydrogen and the aromatic ring of the TSC 
ligand in the E form, as observed previously in analogous 
systems.21,63 
The time dependence of the 1H-NMR spectra of 1-4 (5 
mM) in MeOD-d4 was monitored over 30 days at 298 K, 
and is illustrated for complex 1 in Figure 3.  
As shown in Figure 3, a second set of peaks started to ap-
pear after 24 h (set b) and increased in intensity until a 1:1 
ratio for the two species was reached over a period of 21 
days. Variable temperature 1H-NMR spectra were record-
ed from 298 to 323 K over a period of two hours. The 1:1 
ratio of the a:b peak areas for the two species recorded at 
t=30 days did not change over this temperature range (da-
ta not shown). NOESY experiments carried out for 1 at 
t=30 days, gave evidence that in the b set of peaks there is 
an interaction between the iminic hydrogen of the ligand 
and one of the aromatic protons of the p-cymene (Figure 
S1); this interaction is absent in the a set. A possible ex-
planation for the presence, in solution, of two species 
(corresponding to set a and set b) is the establishment of 
an E/Z equilibrium for the coordinated ligand L1 (Figure 
4). The presence of both the E and the Z isomers of the 
ligand coordinated to the metal center would explain the 
interaction of the iminic proton with the p-cymene moie-
ty, observed for set b in the NOESY experiment. This in-
teraction is possible only for a Z conformation of the lig-
and and not with the E conformation. TSCs are known to 
undergo E/Z interconversion not only as free ligands, but 
also upon coordination (for a mechanistic insight see ref. 
64 and references therein).  
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Scheme 1. Proposed mechanism for the E/Z interconversion process of the coordinated ligand L1 for metal complexes 1 
and 3 in methanol
 
The increase in the percentage of Z isomer suggests that 
the presence of a protic solvent could lead to the for-
mation of a negative charge on the iminic nitrogen and to 
the rotation around the single bond, resulting in the 
isomerization and the formation of the Z isomer, as pro-
posed in Scheme 1. This mechanism is supported by the 
1H-NMR spectrum of the crystals of the complexes in 
methanol. In the X-ray crystal structures of 1 and 3, ob-
tained from a methanol solution, the ligand is in the E 
conformation, but the 1H-NMR spectra of the same crys-
tals recorded in MeOD-d4 showed the presence of both 
isomers of the ligands after 24 h, suggesting that the sol-
vent plays a crucial role in the isomerization process. Re-
cently, examples of pentamethylcyclopentadienyl iridi-
um(III) complexes with TSCs ligands that crystallize with 
the coordinated ligand either with E or Z conformation 
have been reported, confirming the possibility of having 
both isomers in organometallic complexes.65  
Analysis of the data provides evidence that the intercon-
version is slightly faster for the ruthenium compound: at 
298 K the Z isomer takes two weeks to reach the equilib-
rium with the E isomer (1:1 ratio), whereas three weeks are 
required for the osmium complex. The situation is slightly 
different for the complexes 2 and 4. For these complexes a 
second set of signals arises over time (1:1 ratio at t= 7 days 
and 298 K, Figure S2). However, the 1H-NMR spectra of 
these complexes show broad signals in the aromatic re-
gion for the Z isomer (Figure S2). For complex 4, for ex-
ample, at t= 7 days only very broad overlapping signals 
can be seen (Figure S3). The presence of two hydroxyl 
groups on the aromatic ring of the coordinated ligand, 
perhaps gives rise to exchange processes or paramagnetic 
species which broaden signals in the 1H-NMR spectra. 
Due to the long-time scale of the NMR experiments and 
the catecholic nature of the ligand L2, complexes 2 and 4 
can be subjected to oxidation. UV-visible spectroscopy 
was performed in order to verify whether the catechol 
moiety of 2 is involved in oxidation processes in methanol 
solution. The development of a stable and strong absorp-
tion band of a methanol solution of 2 around 337 nm, re-
lated to π-π* transition of the catechol aromatic ring, was 
followed over three days in air (Figure S4). No changes in 
the UV-Vis spectra were detected, indicating that the cat-
echol moiety is not involved in redox processes. 1H-NMR 
spectra of complexes 1-4 were also recorded in an aprotic 
solvent, acetone. In this case, two different sets of signals 
were observed immediately after dissolution in acetone-d6 
at 298 K for all the complexes (Figure 5). Comparison 
with the 1H-NMR obtained in MeOD at t=0 indicates that 
one set of signals is related to the parent organometallic 
compound, as shown in Figure 5 for compound 2. The 
presence of free ligand was excluded by comparison with 
the 1H-NMR spectrum of L2 recorded in acetone-d6. It is 
notable that the 1H-NMR spectra change with time at 298 
K: as shown in Figure 5, both a shift and a modification of 
the pattern of the signals is observed over 2 days. After 
this time the two sets of signals did not change their ratio 
(ca. 1: 1.2). Probably, the second set of signals is due to a 
species containing a coordinated solvent molecule (Fig-
ure 5). 
Due to the limited aqueous solubility of the metal com-
plexes, antiproliferative cell assays were performed using 
stock solutions prepared by dissolution of the compound 
in DMSO followed by dilution with water (final concen-
tration of DMSO 0.5%). The hydrolysis processes are of 
interest as indicators of the stability of the pro-drug un-
der such biological testing conditions, and therefore, the 
solution behavior of 1-4 was investigated also in DMSO-
d6. In the 1H-NMR spectra of 1 and 3 in DMSO-d6 record-
ed at 298 K, three different sets of signals were observed. 
A comparison with the 1H-NMR spectrum of L1 obtained 
in the same solvent confirmed the presence of free ligand 
in a 1:1 ratio vs the metal complex (Figure 6). The two 
doublets observed at 6.08 and 6.00 ppm can be assigned 
to a complex of the type [Os(η6-p-cym)(DMSO)2Cl]Cl, in 
a 1:1 ratio with the parent organometallic complex 1 and 
the free ligand L1. As recently pointed out in the litera-
ture, such a pattern of signals frequently arises after dis-
placement of the organic ligand in [Ru(η6-p-cym)(L)Cl2] 
complexes.66 Ligand dissociation was apparent visually: 
addition of DMSO to the orange powder of 1 leads to an 
orange solution that became green as dissociation pro-
ceeded. 
Complexes 2 and 4 in DMSO-d6, gave a complex pattern 
of 1H-NMR signals. Comparison with the spectrum of 2 in 
MeOD at t=0 indicates that the major set of signals is re-
lated to the parent compound 2. However, other sets of 
signals of lower intensity were observed (Figure S5). Both  
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Figure 5. Aromatic region of the 1H-NMR spectrum of 2 recorded in acetone-d6 at 298 K and followed over 7 days. Red circles 
indicate proton resonances related to the species with a coordinated solvent molecule. 
 
 
Figure 6. Comparison of the aromatic region of the 1H-NMR of complex 1 (upper spectrum) and of the corresponding free 
ligand L1 (lower spectrum) in DMSO-d6 at t=0 and 298 K. 
 
 
sets of signals for the free ligand L2 and the [Os(η6-p-
cym)(DMSO)2Cl]Cl species, each accounted for about 10% 
of the major set. In case of 2 and 4 in DMSO, however, a 
further set of signals, corresponding to about 25% of the 
major set arises in the 1H-NMR spectrum. A possible ex-
planation for this set of signals is the presence of a mono-
solvated species of the type [Os(η6-p-
cym)(DMSO)(L)Cl]Cl (Figure S5).  
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To determine whether the degradation process correlates 
with the concentration of DMSO, the analysis was per-
formed using a solution of D2O-(10%)DMSO, monitored 
for 24 hours to mimic the biological test conditions. The 
1H-NMR spectra of the solutions of 1-4 displayed in all 
cases broad signals, with complicated splitting patterns, 
indicating the presence of several dissociation equilibria 
in solution. This behaviour prevented the use of DMSO in 
biological tests, and therefore, the possibility of preparing 
stock solutions of the compounds in DMF was investigat-
ed. In this case, all the complexes 1-4 presented a unique 
set of signals, stable over 7 days at 298 K (Figure S6). 
Anticancer activity. The anti-proliferative activity of the 
ligands L1 and L2 and of the related osmium and rutheni-
um complexes 1 - 4 towards A549 lung, A2780 ovarian, 
HCT116 colon and PC3 prostate human cancer cells lines 
was investigated. All experiments included untreated 
negative controls and cells treated with the clinical drug 
cisplatin (CDDP) as positive control. The anticancer activ-
ity of the organometallic complexes was investigated by 
performing dose-response studies in the various cell lines 
(Figure S7). A stock solution of each compound was pre-
pared in cell culture medium with DMF to aid solubilisa-
tion. IC50 values (concentrations which caused 50% of cell 
growth inhibition) were determined as duplicates of trip-
licates in two independent sets of experiments and are 
reported in Table 2. Importantly, all experiments de-
signed to determine the antiproliferative activity of the 
complexes included three set of controls (negative, vehi-
cle, and positive). The cell survival in the negative con-
trols and the vehicle controls were compared, and in all 
cases the differences were not statistically significant to 
99%. This indicates that the DMF in the sample solutions 
of complexes 1-4 is not toxic and does not interfere with 
the measurements. Hence, the effects on cell survival ob-
served arise only from the activity of the ligands or the 
metal-based complexes. 
Both thiosemicarbazones L1 and L2 are highly potent to-
wards ovarian cell lines A2780 and A2780Cis. L1 in partic-
ular exhibits IC50 values of 0.85 M and 0.12 M, respec-
tively. Ligand L2 shows submicromolar activity in A2780 
cells (0.27 M) and low micromolar potency in A2780Cis 
(1.23 M). Although the metal complexes are less active 
than their corresponding ligands, they show IC50 values of 
the same order of magnitude as that of CDDP in the pa-
rental cell line and improved resistant factors. Resistance 
factors, calculated as the ratio between the antiprolifera-
tive activity in the parental cell line and its resistant de-
rivative, give an indication of whether the cellular mecha-
nisms of resistance to CDDP are involved in the mecha-
nism of action of the novel metal complexes. It has been 
proposed that the underlying resistance associated with 
A2780Cis involves a two-fold more efficient efflux of the 
platinum drug and a consequent reduction in cellular ac-
cumulation as compared to the parental A2780, as well as 
an increase in DNA-repair mechanisms.67 The corre-
sponding resistance factor for CDDP is 11.25. Complexes 3 
and 4 are particularly promising for overcoming CDDP-
resistance as they have the lowest factors of 1.33 and 3.4, 
respectively, highlighting the importance of the substitu-
ents in the chelating ligands and in particular the incor-
poration of a phenyl ring at the N(3) of the thiosemi-
carbazone, when compared to –NH2. For the A549 lung 
and HCT116 colon cancer cells, there is an improvement 
in the activity of metal complexes compared to their cor-
responding ligands, with thiosemicarbazones L1 and L2 
exhibiting an order of magnitude higher IC50 concentra-
tions than the clinical drug CDDP. It is important to high-
light the 17-fold improvement in potency between L1 and 
its osmium complex 1 increasing from 42 M to 2.4 M in 
A549 cells, as well as, the 12-fold increase in potency be-
tween L2 (33 M) and osmium complex 2 (2.7 M) and 
20-fold compared to ruthenium complex 4 (1.64 M ) in 
the colon HCT116 cell line. The prostate cancer cell line 
PC3, shows mixed results with increments in potency for 
the complexes 2 and 4 derived from L2, but reduction in 
anticancer activity for complexes 1 and 3 derived from L1. 
The former are more active than CDDP in this cell line. 
The observed trends in the anticancer activity, across all 
cell lines and all compounds, point towards complexes 
with ligand L2 being more potent than those which bear 
the ligand L1 and within this, the ruthenium complex 4 
has a more potent activity compared to the osmium ana-
logue. This highlights that the anticancer activity of the 
complexes is not only the result of the metal center per se, 
but also of the nature of the substituents on the thiosemi-
carbazone ligands. 
CONCLUSIONS 
Two new osmium(II) and two ruthenium(II) half-
sandwich complexes [(η6-p-cym)M(L)Cl]Cl containing a 
thiosemicarbazone ligand (L) were synthesized and char-
acterized by 1H-NMR, ESI-MS spectrometry and single 
crystal X-ray crystallography. Complexes 1-4 are structur-
ally very similar and characterized by a distorted octahe-
dral geometry. In the crystal structures, the E configura-
tion of the thiosemicarbazone ligand was evident.  
In a protic solvent, such as methanol, an interconversion 
takes place and peaks for both E and Z isomers of the lig-
and appear in the 1H-NMR spectrum: the conformational 
change in the ligand is probably promoted by the interac-
tion of the solvent with the acidic proton of the aromatic 
ring. 
When the complexes were dissolved in the non-protic, 
coordinating acetone, or in DMSO, solvation reactions 
prevailed. On the contrary, in DMF solution, the com-
plexes remained stable. Hence DMF (5%) and not DMSO 
was used to aid solubility for cancer cell screening. Prom-
ising results were obtained, particularly towards HCT116 
colon cancer cells, in which the metal complexes are up to 
20-fold more potent than the corresponding free ligand 
L2. Ruthenium complex 3 shows promising anticancer ac-
tivity and the possibility to overcome CDDP resistance as 
demonstrated by the data for A2780 ovarian cancer cells 
and its derived CDDP-resistant cell line A2780Cis. In fact 
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all complexes showed lower resistance factors than the 
clinical drug cisplatin. 
Future work will be aimed at optimizing the pharmaco-
logical profiles of these complexes, and especially to in-
crease stability under biological testing conditions. 
 
 
Table 2. IC50 values (M) for L1 and L2 and related metal complexes 1-4 towards human ovarian (A2780), cisplatin-
resistant ovarian (A2780Cis), lung (A549), colon (HCT116) and prostate (PC3) cancer cell lines. Clinical drug cisplatin 
(CDDP) is used as positive control. 
 
 
Cell lines 
IC50 /M 
Resistance 
Factors 
Compound A2780 A2780Cis A549 HCT116 PC3 A2780Cis/A2780 
L1 0.85±0.03 0.12±0.02 42±2 30.6±0.5 6.1±0.1 0.14 
L2 0.27±0.02 1.23±0.08 23±1 33±5 4.6±0.2 4.55 
1 1.60±0.02 6.6±0.9 2.4±0.2 24±2 21±1 4.12 
2 0.75±0.08 7.2±0.1 17±1 2.7±0.2 1.60±0.08 9.60 
3 4.2±0.3 5.6±0.8 - 10.5±0.3 19±1 1.33 
4 0.36±0.03 1.25±0.06 - 1.64±0.08 1.38±0.04 3.47 
CDDP 1.2 ± 0.2 13.5 ± 0.3 3.1 ± 0.2 5.2 ± 0.1 9.8 ± 0.4 11.25 
 
EXPERIMENTAL SECTION 
Materials. All commercial reagents were used as received. 2-
Hydroxy-3-metoxybenzaldehyde, 2,3-dihydroxybenzaldehyde, 
thiosemicarbazide and 4-phenylthiosemicarbazide were pur-
chased from Sigma-Aldrich; OsCl3∙nH2O and RuCl3∙nH2O from 
Alfa Aesar. All reactions were performed under an inert atmos-
phere of nitrogen using standard Schlenk line techniques and all 
glassware was oven-dried (120°C) overnight. Dry solvents were 
purchased from Sigma-Aldrich and stored under nitrogen. [(η6-
p-cym)OsCl2]2 and [(η6-p-cym)RuCl2]2 were synthesized accord-
ing to literature procedures.49,68 
Cell Culture. Cell lines used in this work included A2780 hu-
man ovarian carcinoma and its cisplatin resistant variant 
A2780Cis, A549 human caucasian lung carcinoma, HCT116 hu-
man colon carcinoma, and PC3 human prostate carcinoma. They 
were all obtained from the European Collection of Cell Cultures 
(ECACC), used between passages 5 and 18 and were grown in 
Roswell Park Memorial Institute medium (RPMI-1640) supple-
mented with 10% (v/v) of fetal calf serum, 1% (v/v) of 2 mM glu-
tamine and 1% (v/v) penicillin/streptomycin. They were grown 
as adherent monolayers at 310 K in a 5% CO2 humidified atmos-
phere and passaged at ca. 70-80% confluence. 
In vitro Growth Inhibition Assay. Briefly, 5000 cells were 
seeded per well in 96-well plates. The cells were pre-incubated 
in drug-free media at 310 K for 48 h before adding different con-
centrations of the compounds to be tested. A stock solution of 
the metal complex was firstly prepared in 5% DMF (v/v) and a 
mixture 0.9% saline and medium (1:1) (v/v) following serial dilu-
tions in RPMI-1640. The drug exposure period was 24 h. After 
this, supernatants were removed by suction and each well was 
washed with PBS. A further 72 h was allowed for the cells to re-
cover in drug-free medium at 310 K. The SRB assay was used to 
determine cell viability. Absorbance measurements of the solu-
bilised dye allowed the determination of viable treated cells 
compared to untreated controls. IC50 values (concentrations 
which caused 50% of cell growth inhibition), were determined as 
duplicates of triplicates in two independent sets of experiments 
and their standard deviations were calculated. All experiments 
included three sets of controls: a) negative controls, in which 
cells were kept untreated, b) vehicle controls, in which cells were 
exposed to medium with vehicle only (in this case DMF, at the 
highest concentration used for the complexes), and c) positive 
controls, in which cells were exposed to different concentrations 
of the anticancer drug cisplatin. 
Syntheses. General procedure for the synthesis of thiosemi-
carbazone ligands (L1–L2). 
The synthesis of the ligands L1 and L2 was performed using the 
following adapted literature procedure.54,55 The appropriate al-
dehyde (1 mol equiv) was dissolved in a hot toluene solution (20 
ml) containing few drops of glacial acetic acid. An equimolar 
amount of the corresponding thiosemicarbazide (1 mol equiv) 
was added to the solution and the reaction mixture was heated 
under reflux for 8 h. The solution was cooled to ambient tem-
perature and the TSC ligands were obtained as precipitate. After 
filtration the solid was washed several times with toluene and 
ether and dried under vacuum. 
N-(2-hydroxy)-3-metoxybenzylidenethiosemicarbazide (L1). 
White powder, yield: 87%. 1H-NMR (DMSO-d6): δ 11.39 (s, 1H, 
NH), 9.17 (s, 1H, OH), 8.40 (s, 1H, CH=N), 8.10-7.88 (2s, 1H+1H, 
NH2), 7.52 (d, 1H, J= 7.5 Hz, CHAr), 6.95 (d, 1H, J=7.5 Hz, CHAr), 
6.75 (t, 1H, J=7.5 Hz, CHAr), 3.81 (s, 3H, OCH3). ESI-MS 
(C9H11N3SO2, MeOH): m/z= 225 [M+H]+.  
N-(2,3-dihydroxybenzylidene)-3-phenylthiosemicarbazide (L2). 
White powder, yield: 81%. 1H-NMR (DMSO-d6): δ 11.76 (s, 1H, 
NH), 10.01-9.54 (2s, 1H+1H, OH), 9.01 (s, 1H, NH), 8.49 (s, 1H, 
CH=N), 7.56 (d, 2H, J=7.5 Hz, CHAr), 7.49 (d, 2H, J=8 Hz, CHAr), 
7.34 (t, 2H, J=7.5 Hz, CHAr), 7.17 (t, 1H, J=7.5 Hz, CHAr), 6.81 (d, 
1H, J=8 Hz, CHAr), 6.64 (t, J=8 Hz, CHAr). ESI-MS (C14H13N3SO2, 
MeOH): m/z= 287 [M+H]+.  
General procedure for the metal complexes synthesis (1-4). The 
TSC ligand (2 mol equiv) was dissolved in dry methanol (20 ml) 
and the solution was acidified with the addition of one drop of 
HCl 37%. [(η6-p-cym)MCl2]2 (1 mol equiv) was dissolved in 10 mL 
of dry dichloromethane and the solution was added to the previ-
ous one. The reaction mixture was maintained under stirring at 
ambient temperature under nitrogen for 24 h. The volume was 
then reduced to half on the rotary evaporator, and diethyl ether 
was added until the precipitation of a solid occurred. The prod-
uct was then collected by filtered and dried under vacuum. 
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[Os(η6-p-cym)Cl(L1)]Cl (1). Orange powder, yield: 98%. Anal. 
Calcd for C19H25Cl2N3O2OsS: C, 36,77; H, 4,06; N, 6,77. Found: 
C, 36,51; H, 4,56; N, 6,70. 1H-NMR (MeOD-d4): δ 8.76 (s, 1H, 
CH=N), 7.86 (d, 1H, J=8 Hz, CHAr), 7.25 (d, 1H, J=8 Hz, CHAr), 7.01 
(t, 1H, J=8 Hz, CHAr), 5.87 (d, 1H, J=5.5 Hz, CHp-cym), 5.44 (d, 1H, 
J=5.5 Hz, CHp-cym), 5.31 (d, 1H, J=5.5 Hz, CHp-cym), 4.90 (d, 1H, 
J=5.5 Hz, CHp-cym), 3.99 (s, 3H, OCH3), 2.54 (m, 1H, J=7 Hz, CHi-
prop), 2.16 (s, 3H, CH3), 1.20-1.11 (2d, 3H+3H, J=7 Hz, CH3i-prop). ESI-
MS (positive ions, MeOH): m/z= 585 [M-Cl]+.  
Crystals suitable for X-ray analysis were obtained by vapour dif-
fusion of ether in saturated methanol solution of the compound. 
[Os(η6-p-cym)Cl(L2)]Cl (2). Orange powder, yield: 72%. Anal. 
Calcd for C24H27Cl2N3O2OsS.H2O: C, 41,14; H, 4,17; N, 6,00. 
Found: C, 40,81; H, 4,16; N, 6,23. 1H-NMR (MeOD-d4): δ 8.87 (s, 
1H, CH=N), 7.75 (d, 1H, J=7 Hz, CHAr), 7.48 (t, 2H, J=7 Hz, CHAr), 
7.43 (d, 2H, J=7 Hz, CHAr), 7.35 (t, 1H, J=7 Hz, CHAr), 7.08 (dd, 1H, 
J=8 Hz, CHAr), 6.88 (t, 1H, J=8 Hz, CHAr), 5.86 (d, 1H, J=5.5 Hz, 
CHp-cym), 5.49 (d, 1H, J=5.5 Hz, CHp-cym), 5.31 (d, 1H, J=5.5 Hz, 
CHp-cym), 4.93 (d, 1H, J=5.5 Hz, CHp-cym), 2.55 (m, 1H, J=7 Hz, CHi-
prop), 1.21-1.13 (2d, 3H+3H, J=7 Hz, CH3i-prop). ESI-MS (positive 
ions, CH3OH): m/z= 648 [M-Cl]+.  
Crystals suitable for X-ray analysis were obtained by slow evapo-
ration of a saturated acetone solution. 
[Ru(η6-p-cym)Cl(L1)]Cl (3). Red powder, yield: 78%. Anal. Calcd 
for C19H25Cl2N3O2RuS.CH3OH: C, 42,63; H, 5,19; N, 7,46. 
Found: C, 41,92; H, 5,21; N, 7,34.  1H-NMR (MeOD-d4): δ 8.79 (s, 
1H, CH=N), 8.06 (d, 1H, J=8 Hz, CHAr), 7.28 (d, 1H, J=8 Hz, CHAr), 
7.07 (t, 1H, J=8 Hz, CHAr), 5.71 (d, 1H, J=6 Hz, CHp-cym), 5.17 (d, 
1H, J=6 Hz, CHp-cym), 5.04 (d, 1H, J=6 Hz, CHp-cym), 4.00 (s, 3H, 
OCH3), 2.64 (m, 1H, J=7 Hz, CHi-prop), 2.10 (s, 3H, CH3), 1.20-1.14 
(2d, 3H+3H, J=7 Hz, CH3i-prop). ESI-MS (positive ions, CH3OH): 
m/z= 496 [M-Cl]+.  
Crystals suitable for X-ray analysis were obtained by vapour dif-
fusion of ether in a saturated methanol solution of the com-
pound. 
[Ru(η6-p-cym)Cl(L2)]Cl (4). Red powder, yield: 87%. Anal. Calcd 
for C24H27Cl2N3O2RuS.CH3COCH3: C, 49,77; H, 5,10; N, 6,45. 
Found: C, 49,54; H, 5,23; N, 7,01. 1H-NMR (MeOD-d4): δ 8.90 (s, 
1H, CH=N), 7.95 (dd, 1H, J=8 Hz, J’=1 Hz, CHAr), 7.48 (t, 2H, J=7.5 
Hz, CHAr), 7.41 (d, 2H, J=7.5 Hz, CHAr), 7.37 (d, 1H, J=7 Hz, CHAr), 
7.09 (td, 1H, J=8 Hz, J’=1 Hz, CHAr), 6.94 (t, 1H, J=7.5 Hz, CHAr), 
5.86 (d, 1H, J=5.5 Hz, CHp-cym), 5.49 (d, 1H, J=5.5 Hz, CHp-cym), 5.31 
(d, 1H, J=5.5 Hz, CHp-cym), 4.93 (d, 1H, J=5.5 Hz, CHp-cym), 2.55 (m, 
1H, J=7 Hz, CHi-prop), 1.21-1.13 (2d, 3H+3H, J=7 Hz, CH3i-prop). ESI-
MS (positive ions, CH3OH): m/z= 558 [M-Cl]+.  
Crystals suitable for X-ray analysis were obtained by slow evapo-
ration of a saturated acetone solution of the compound. 
X-Ray Crystallography. Diffraction data were obtained on an 
Xcalibur Gemini diffractometer four-circle system with a Ruby 
CCD area detector using Mo Kα radiation. Absorption correc-
tions were applied using ABSPACK69. The crystals were mounted 
on a glass fiber with Fromblin oil and kept at 150(2) K during da-
ta collection. Using Olex270, the structure was solved with the 
ShelXT71 structure solution program using Direct Methods and 
refined with the ShelXL refinement package using least squares 
minimisation. 
NMR spectroscopy. 1H-NMR spectra were obtained in 5 mm 
NMR precision tubes at 298 K on either Bruker DPX-300 or 
DPX-400 NMR spectrometers. 1H-NMR chemical shift were in-
ternally referenced to (CHD2)(CD3)SO (2.50 ppm) for DMSO-d6, 
CD3OD (3.31 ppm) for methanol-d4, D2O (4.79 ppm) for water-d2, 
(CD3)2CO (2,05 ppm) for acetone-d6. 1H-NMR spectra at variable 
temperature were obtained in 5 mm NMR precision tube on 
Bruker AV-III 400 NMR spectrometer. NOESY spectra were ob-
tained in 5 mm NMR precision tubes at 298 K on Bruker DPX-
500 NMR spectrometer. 1H-NMR peaks were internally refer-
enced to CHD2OD (3.31 ppm) for methanol-d4 or 1,4-dioxane  
(3.66 ppm). All data processing was carried out using Mes-
tReNova 9.0.1. 
Mass Spectrometry. Electrospray ionization mass spectra (ESI-
MS) were obtained by preparing the sample in methanol using a 
Bruker Esquire 2000 ion trap spectrometer. Samples were pre-
pared in methanol. The mass spectra were recorded with a scan 
range of m/z 50-500 for positive ions for L1-L2 and m/z 400-1000 
for positive ions for the complexes 1-4. 
UV-vis spectroscopy. UV-vis absorption spectra were recorded 
on a Cary 300 spectrometer using quartz cuvettes of 1 cm path-
length (600 μL). The sample temperature was adjusted to 298 K 
by PTP1 Peltier temperature controller. Samples were prepared 
in methanol. Spectra were recorded from 200 to 600 nm. Data 
were processed with Microsoft Excel 14.3.6 Mac version. 
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